AKAP6 Kinase binding domain (KBD) peptide improves cardiac function in HFpEF pigs
Ontology highlight
ABSTRACT:
ORGANISM(S): Sus scrofa
PROVIDER: GSE335057 | GEO | 2026/07/28
REPOSITORIES: GEO
Similar Datasets
Project description:The purpose of this RNA-seq analysis is to investigate the effects of KBD expression on gene expression profiles in HFpEF pig hearts.
2026-07-28 | GSE335365 | GEO
Project description:AKAP6 Kinase binding domain (KBD) peptide improves cardiac function in HFpEF pigs
| PRJNA1477183 | ENA
Project description:AKAP6 Kinase binding domain (KBD) peptide improves cardiac function in HFpEF pigs [scRNA-seq]
| PRJNA1478014 | ENA
Project description:HFpEF mouse model was established by a \"double hit\" of L-NAME and high-fat diet (60% fat). 5-week-old C57BL/6N mice were given the above intervention for 5 weeks (Early HFpEF group) or 12 weeks (Advanced HFpEF group). 17-week-old mice fed a normal diet were used as the Control group. After adequate perfusion, the hearts were harvested. Ventricular RNA was extracted for RNA sequencing.
2025-12-31 | E-MTAB-15255 | biostudies-arrayexpress
Project description:Aims: Despite the high prevalence of heart failure with preserved ejection fraction (HFpEF), the pathomechanisms remain elusive and specific therapy is lacking. Disease-causing factors include metabolic risk, notably obesity. However, proteomic changes in HFpEF are poorly understood, hampering therapeutic strategies. We sought to elucidate how metabolic syndrome affects cardiac protein expression, phosphorylation and acetylation in the Zucker diabetic fatty/Spontaneously hypertensive heart failure F1 (ZSF1) rat HFpEF model, and to evaluate some changes regarding their potential for treatment. Main methods: ZSF1 obese and lean rats were fed a Purina diet up to the onset of HFpEF in the obese animals. We quantified the proteome, phosphoproteome and acetylome of ZSF1 obese versus lean heart tissues by mass spectrometry and singled out targets for site-specific evaluation. Key findings: We found the acetylome of ZSF1 obese versus lean hearts more severely altered (21% of proteins changed) than the phosphoproteome (9%) or proteome (3%). Proteomic alterations, confirmed by immunoblotting, indicated low-grade systemic inflammation and endothelial remodeling in obese hearts, but low nitric oxide-dependent oxidative/nitrosative stress. Altered acetylation in ZSF1 obese hearts mainly affected pathways important for metabolism, energy production and mechanical function, including hypo-acetylation of mechanical proteins but hyper-acetylation of proteins regulating fatty acid metabolism. Hypo-acetylation and hypo-phosphorylation of elastic titin in ZSF1 obese hearts explained myocardial stiffening. Significance: Cardiometabolic syndrome alters posttranslational modifications, notably acetylation, in experimental HFpEF. Pathway changes implicate a HFpEF signature of low-grade inflammation, endothelial dysfunction, metabolic and mechanical impairment, and suggest titin stiffness and mitochondrial metabolism as promising therapeutic targets.
2022-10-12 | PXD036259 | Pride
Project description:<p>Increased protein acetylation is frequently observed in the failing heart, including in hearts with heart failure with preserved ejection fraction (HFpEF). However, the role of protein acetylation in cardiac metabolic impairments during the pathogenesis of HFpEF remains insufficiently investigated. In this study, a two-hit strategy, involving a high-fat diet and Nω-nitro-L-arginine methyl ester (L-NAME), was employed to induce the HFpEF model in mice. Significant cardiac diastolic dysfunction, pathological remodeling, and enhanced protein hyperacetylation were observed in the hearts of the two-hit HFpEF mice. Acetylome profiling revealed that the hyperacetylated proteins were predominantly localized to mitochondria and enriched in metabolic pathways, particularly in fatty acid oxidation (FAO). Furthermore, the HFpEF heart exhibited reduced FAO capacity and abnormal lipid accumulation. Activation of mitochondrial protein deacetylation restored FAO capacity and alleviated cardiac dysfunction in the HFpEF heart, whereas inhibition of mitochondrial deacetylase directly induced lipid metabolism disorders in cardiomyocytes. Notably, we identified Dlat, a pyruvate metabolism enzyme, as the key transacetylase responsible for mitochondrial protein hyperacetylation in the HFpEF heart. Overexpression of Dlat enhanced FAO-related protein acetylation and exacerbated cardiac lipid metabolism disturbances, thereby inducing pathological changes resembling the HFpEF phenotype. In contrast, Dlat knockdown effectively mitigated FAO inhibition and functional impairment in the two-hit HFpEF mice. Through discovery-driven approaches, we demonstrated that Dlat directly binds to the alpha subunit of mitochondrial trifunctional protein (HADHA) and triggers its acetylation at the K728 site, thereby inactivating HADHA enzymatic activity. Reactivating HADHA, either by cardiac-specific HADHA overexpression or oral administration of a biogenic polyamine, restored cardiac FAO capacity and prevented the development of HFpEF. Our study provides a mechanistic basis linking protein hyperacetylation, FAO inhibition, and the development of HFpEF. Activation of mitochondrial deacetylase or enhancement of cardiac FAO capacity may offer novel strategies for restoring cardiac metabolic homeostasis and function in HFpEF.</p>
2025-09-01 | MTBLS12919 | MetaboLights
Project description:Background: Heart failure with preserved ejection fraction (HFpEF) constitutes more than half of all heart failure but has few effective therapies. Recent human myocardial transcriptomics and metabolomics have revealed major differences between HFpEF, HF with reduced EF (HFrEF), and controls. How this translates at the protein level is currently unknown. Methods: Myocardial tissue from patients with HFpEF and non-failing donor controls was analyzed by data-dependent (DDA, n=10 HFpEF, n=9 controls) and data-independent (DIA, n=44 HFpEF, n=5 controls) mass spectrometry-based proteomics. Previously reported myocardial proteomic data from end-stage HFrEF and controls were also used. Differential protein expression analysis, machine learning and pathway enrichment were integrated with clinical characteristics and myocardial transcriptomics. Results: DDA-MS proteomics identified 88 significantly upregulated and 248 down-regulated proteins in HFpEF vs controls, out of 1996 identified proteins. Principal component analysis of DDA-MS proteomics found HFpEF was separated into 2 sub-groups: one being similar to controls the other quite disparate. Top proteins contributing to the separation of HFpEF subgroups were enriched in actin/myosin binding, regulation of DNA replication/repair, transcription, and translation. Downregulated proteins in HFpEF vs controls were enriched in pathways related to ribosome structure, transmembrane transporters, metabolic enzymes, and oxidative phosphorylation (OxPhos) proteins. Enriched pathways for proteins upregulated in HFpEF related to actin and phospholipid binding, growth factor signaling, kinase regulation, and glycolysis. Ingenuity pathway analysis predicted downregulation of protein translation, mitochondrial function, and glucose and fat metabolism in HFpEF. OxPhos gene (increased) versus protein (decreased) expression was discordant in HFpEF. The second DIA proteomic analysis also yielded two HFpEF sub-groups; the one most different from controls also having reduced OxPhos and protein translation pathways. A higher proportion of these patients also had severe obesity. Conclusions: Integrative proteomics, transcriptomics, and pathway analysis supports a translational defect particularly involving mitochondrial, ribosomal and protein translation proteins in HFpEF. Patients with more distinct proteomic signatures from control were more often very obese. The results support therapeutic efforts targeting metabolism, mitochondrial function, and protein translation in this subgroup.
2024-03-05 | PXD045677 | Pride
Project description:Heart failure with preserved ejection fraction (HFpEF) accounts for half of heart failure cases and is characterised by reduced pericyte coverage. While the contributions of other cardiac cell types to HFpEF are well-studied, the role of pericytes remains less understood. Using murine single-nucleus RNA sequencing to study cardiac pericytes in HFpEF, we identified reduced STAT3 expression as a hallmark of HFpEF pericytes. Mechanistic studies in vitro revealed that STAT3 deletion induces cellular senescence and impairs pericyte adhesion, recapitulating HFpEF-like characteristics. These findings suggest that STAT3 is crucial for maintaining pericyte homeostasis and highlight its reduction as a potential driver of pericyte loss, a defining feature of HFpEF.
2025-04-25 | E-MTAB-15019 | biostudies-arrayexpress
Project description:To investigate the effect of butyrate on cardiac transcripts in western-diet induced pre-HFpEF
2023-03-01 | GSE221195 | GEO
Project description:Background: HFpEF is a heterogeneous clinical picture that is closely related to extracardiac comorbidities such as obesity, hypertension and diabetes and is associated with chronic, low-grade systemic inflammation. Previous studies on myocardial biopsies of HFpEF patients showed intramyocardial inflammatory activity, suggesting that the inflammatory processes in HFpEF are predominantly systemic and exhibit compartment specific-patterns. Methods: We performed single cell RNA sequencing (scRNA-seq) of peripheral blood mononuclear cells (PBMCs) of HFpEF patients (n=6), HFrEF patients (n=8) and healthy controls (n=7) taking obesity status into account. For validation, bulk RNA sequencing was performed on whole blood samples. In parallel, the systemic immune cell response was investigated in a HFpEF mouse model (induced by a high-fat diet plus L-NAME), with one group additionally administered the anti-inflammatory agent nitro-oleic acid (NO₂-OA). Results: Analysis of human PBMCs revealed a HFpEF-specific inflammatory fingerprint, which manifested in obesity-related increased expression of cytokine signaling genes (e.g. CCL2, TNF) and obesity-independent increases in mitochondrial-associated activity. In the mouse model, HFpEF animals showed a comparable increase in inflammatory markers, with treatment with NO₂-OA leading to a partial normalization of immunological signatures and a significant improvement in diastolic function. Conclusion: Our results demonstrate that the immune cells of patients with HFpEF are characterized by a distinct transcriptional immune signature that differs from that of patients with HFrEF. The conserved immunological signatures between humans and mice, and the beneficial effect of NO₂-OA in a preclinical model, provide important translational insights and generate hypotheses for personalized interventions in HFpEF.
2025-07-28 | GSE298173 | GEO